Selvita to Present Data From Multiple Oncology Programs at AACR 2019 Annual Meeting

KRAKOW, Poland, March 4, 2019 /PRNewswire/ -- Selvita (WSE: SLV), a clinical stage drug discovery and development
company engaged in the research and development of novel cancer therapies, today announced that data from multiple Selvita oncology programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place March 29 to April 3, 2019, in Atlanta. Data presented will include results from the SEL120, CDK8 kinase inhibitor program as well as data from small-molecule STING agonist and dual A2A/A2B adenosine receptors antagonist programs.

Details of the poster presentations are as follows:

Presentation: "SEL120, a potent and specific inhibitor of CDK8 induces complete remission in human patient derived xenograft models of acute myeloid leukemia"
Abstract Number: 1306
Session: Novel Targets and Pathways
Date and Time: Monday, April 1, 8:00 AM - 12:00 PM

Presentation: "Novel dual A_2A A_2B adenosine receptor antagonists for cancer immunotherapy: in vitro and in vivo characterization"
Abstract Number: 4135
Session: Novel Immunomodulatory Agents 2
Date and Time: Tuesday, April 2, 1:00 PM - 5:00 PM

Presentation: "Discovery and characterization of next-generation small molecule direct STING agonists"
Abstract Number: 4983
Session: Immunomodulators and Response to Therapy
Session Date and Time: Wednesday, April 3, 8:00 AM - 12:00 PM

Presentations will be located at the Georgia World Congress Center, Exhibit Hall B. Additional information is available at on the AACR conference website at http://www.aacr.org.

About Selvita

Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways and other cancer-related targets. SEL24 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K.

Contact:

Julia Balanova (investors)
+1-646-378-2936    
[email protected] 

Rich Allan (media)
+1-646-378-2958
[email protected] 

Malgorzata Syjud (corporate)
+48-660-797-362
[email protected]

SOURCE Selvita

Related Links

https://selvita.com/

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED